Foam cell-derived 4-hydroxynonenal induces endothelial cell senescence in a TXNIP-dependent manner by Y. Riahi et al.
Foam cell-derived 4-hydroxynonenal induces
endothelial cell senescence in a TXNIP-dependent manner
Yael Riahi a, b, Nurit Kaiser b, Guy Cohen a, Ihab Abd-Elrahman a, Galia Blum a, Oz M. Shapira c,
Tomer Koler c, Maya Simonescu d, Anca V. Sima d, Neven Zarkovic e, Kamelija Zarkovic f,
Marica Orioli g, Giancarlo Aldini g, Erol Cerasi b, Gil Leibowitz b, Shlomo Sasson a, *
a Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University, Jerusalem, Israel
b Endocrinology and Metabolism Service, Department of Medicine,
The Hebrew University-Hadassah Medical Center, Jerusalem, Israel
c Department of Cardiothoracic Surgery, The Hebrew University-Hadassah Medical Center, Jerusalem, Israel
d Institute of Cellular Biology and Pathology N. Simionescu of The Romanian Academy, Bucharest, Romania
e Laboratory for Oxidative Stress, Rudjer Boskovic Institute, Zagreb, Croatia
f Department of Pathology, School of Medicine, University of Zagreb, Zagreb, Croatia
g Department of Pharmaceutical Sciences, Universita degli Studi di Milano, Milan, Italy
Received: July 30, 2014; Accepted: January 15, 2015
Abstract
Vascular endothelial cell (VEC) senescence is considered an early event in the development of atherosclerotic lesions. Stressful stimuli, in par-
ticular oxidative stress, have been linked to premature senescence in the vasculature. Foam cells are a major source of reactive oxygen species
and may play a role in the induction of VEC senescence; hence, we investigated their involvement in the induction of VEC senescence in a
co-culture transwell system. Primary bovine aortic endothelial cells, exposed to the secretome of THP-1 monocyte-derived foam cells, were
analysed for the induction of senescence. Senescence associated b-galactosidase activity and the expression of p16 and p21 were increased,
whereas phosphorylated retinoblastoma protein was reduced. This senescent phenotype was mediated by 4-hydroxnonenal (4-HNE), a lipid per-
oxidation product secreted from foam cells; scavenging of 4-HNE in the co-culture medium blunted this effect. Furthermore, both foam cells
and 4-HNE increased the expression of the pro-oxidant thioredoxin-interacting protein (TXNIP). Molecular manipulation of TXNIP expression
confirmed its involvement in foam cell-induced senescence. Previous studies showed that peroxisome proliferator-activated receptor (PPAR)d
was activated by 4-hydroalkenals, such as 4-HNE. Pharmacological interventions supported the involvement of the 4-HNE-PPARd axis in the
induction of TXNIP and VEC senescence. The association of TXNIP with VEC senescence was further supported by immunofluorescent staining
of human carotid plaques in which the expression of both TXNIP and p21 was augmented in endothelial cells. Collectively, these findings sug-
gest that foam cell-released 4-HNE activates PPARd in VEC, leading to increased TXNIP expression and consequently to senescence.
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Introduction
Atherosclerosis is a chronic inflammatory disease affecting certain
areas in the arteries, which are characterized by disturbed blood flow
[1–3]. Impaired function of the vascular endothelium precedes the
development of atherosclerotic lesions. Whilst this impairment is part
of the natural ageing process [4–6], additional pathophysiological fac-
tors promote and accelerate atherosclerosis, among which are hyper-
glycaemia, dyslipidaemia and hypertension [7–9]. These conditions
may induce oxidative stress [10], endoplasmic reticulum (ER) stress
[11] and inflammation [12, 13], which have emerged as major detri-
mental factors that induce endothelial cell dysfunction.
Cellular senescence has been linked to the development of vascu-
lar endothelial cell (VEC) dysfunction in atherosclerosis (reviewed in
[14, 15]). Senescence, which was initially considered part of the
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ageing process of cultured cells, and termed ‘replicative senescence’,
has been linked to progressive shortening of the telomeres due to
successive cell divisions (reviewed in [16]). Senescence could also
result from telomere-independent events, in which mitotically compe-
tent cells respond to stress, most often oxidative stress, by growth
arrest. In contrast with replicative senescence, stress-induced prema-
ture senescence (SIPS) is potentially reversible [17]. Senescent cells
are characterized by increased expression of the cyclin-dependent
kinase inhibitors p21 and p16, and reduced phosphorylated pRb,
which lead to cell cycle arrest at the G0/G1 checkpoint by inactivating
members of the transcriptional factor family E2F [18]. In addition,
senescent cells exhibit increased cell size and increased cytoplasmic
activity of senescence-associated b-galactosidase (SA-b-Gal) [14,
15]. Senescent VEC were observed in areas of atherosclerotic lesions
in the human aorta and coronary arteries, and in animal models of
atherosclerosis [14, 19–23]. Cultured VEC were also shown to
develop replicative- and stress-induced senescence [24], associated
with changes in morphology and gene expression, causing impair-
ment of important cell functions such as endothelium-dependent
vasodilation, angiogenesis, vascular healing and increased expression
of inflammatory mediators [14, 15].
The oxidized form of LDL-cholesterol (OxLDL) plays a central
role in the pathophysiology of atherosclerosis, affecting key
stages of this process. At the initial stage, it binds to scavenger
receptors on VEC surface and induces the expression of adhesion
molecules that facilitate monocyte adhesion and migration to the
sub-endothelial layer [25]. OxLDL transverses the endothelial bar-
rier and enters the sub-endothelium, where it transforms mono-
cytes into macrophages, which become lipid-laden foam cells
[26]. The latter contribute to the expansion of the lipid core in
the atherosclerotic plaque and exacerbate oxidative stress. Indeed,
foam cells produce high levels of superoxide, nitric oxide and
hydrogen peroxide [27].
Cells exposed to high levels of reactive oxygen species (ROS)
often respond by augmenting the generation of 4-hydroxynonenal
(4-HNE), the non-enzymatic peroxidation product of n-6 polyun-
saturated fatty acids (PUFA) [28–31]. In addition, 4-HNE induces
the expression of monocyte chemoattractant proteins [32], alters
the cell cycle [33, 34] and promotes apoptosis [35]. Moreover, it
may induce ER stress and impair endothelial barrier and coagula-
tion functions [36–38]. Cytotoxic effects of 4-HNE are attributed
to its covalent interactions with nucleophilic moieties in proteins,
DNA and phospholipids [39, 40]. Excessive accumulation of 4-
HNE-modified proteins has been shown to inhibit the proteasome
[41]. However, recent studies claim that low non-cytotoxic con-
centrations of 4-hydroxyalkenals, including 4-HNE and 4-hydrox-
ydodecadienal, function as signalling molecules by activating the
nuclear receptor peroxisome proliferator-activated receptor (PPAR)
d [31, 42–44]. Overall, the accumulation of foam cells in the
sub-endothelial space may promote atherosclerosis by generating
oxidative stress along with accumulation of lipid peroxidation
products that affect VEC.
The thioredoxin (TRX) system regulates oxidative stress in vari-
ous tissues, including the vascular endothelium [45]. This antioxidant
system consists of TRX, TRX-reductase, NADPH and the natural TRX
inhibitor, the thioredoxin-interacting protein (TXNIP) [46]. Thioredox-
in is ubiquitously expressed in VEC, where it scavenges ROS, pre-
vents apoptosis and promotes angiogenesis [47, 48]. TXNIP impairs
the reducing activity of TRX by interacting with the catalytic site of
reduced TRX, leading to increased ROS accumulation [49]. Moreover,
TXNIP has been shown recently to mediate endothelial cell inflamma-
tion in response to disturbed blood flow by increasing monocyte
adhesion [50]. Lipid peroxidation products, such as 4-HNE and acro-
lein, inhibit TRX activity by binding to Cys73, which is placed out of
the catalytic domain, thus inducing a conformational change; this has
been associated with increased ROS production and enhanced mono-
cyte adhesion to VEC [51]. These findings suggest that the TRX sys-
tem is important for VEC function and protects against
atherosclerosis.
The present study was designed to investigate the effects of foam
cells-derived lipid peroxidation products on VEC senescence. Our
findings show that 4-HNE produced by foam cells induces senes-
cence in VEC by activating PPARd, resulting in increased TXNIP
expression.
Materials and methods
Materials
All tissue culture media and reagents were purchased from Biological
Industries (Beit Haemek, Israel). Transwell plates and inserts were
from Nunc (Roskilde, Denmark). Calbiochem (Darmstadt, Germany)
supplied GW501516 and 4-HNE; Sigma-Aldrich (Rehovot, Israel) the
anti a-tubulin antibody, GSK0660, Oil red O, phorbol 12-myristate 13-
acetate (PMA), WY14643 and troglitazone; Abcam (Cambridge, MA,
USA) supplied the senescence-associated b-galactosidase detection kit
and the following polyclonal antibodies: rabbit anti-p21, rabbit anti-p16
and anti-pRB (phospho-Ser795). Mouse anti-TXNIP was from MBL Ltd
(Nagoya, Japan) and horseradish peroxidase-conjugated anti-rabbit IgG
from Jackson ImmunoResearch (West Grove, PA, USA). Mirus Bio-
Corporation (Madison, WI, USA) supplied the TransIT-LT1reagent. Pro-
mega (Madison, WI, USA) supplied the dual-luciferase reporter assay
system. The TXNIP small-interfering RNA (siRNA) was synthesized by
GE Dharmacon (Lafayette, CO, USA). Qiagen (Hilden, Germany) sup-
plied the negative (scrambled) control siRNA (allstars negative con-
trol). The pcDNA3 and pEGFP-N1 plasmids were kindly provided by
Dr. R. Hertz (The Hebrew University Faculty of Medicine, Jerusalem,
Israel). The pSVPORT1-hRXR vector and the 3xPPAR response ele-
ment (PPRE)-TK-luciferase plasmid were courtesy of Dr. B.M. Spiegel-
man (Dana Farber Cancer Institute, Boston, MA, USA). The pCMX-
hPPARc1 and pCMX-hPPARc2 plasmids and the respective empty
plasmids were kindly provided by Dr. R. Evans (Howard Hughes Med-
ical Institute, La Jolla, CA, USA). Dr. B. Staels (Institut Pasteur de
Lille, Lille, France) kindly provided the pSG5 and pSG5-hPPARa vec-
tors. The PPARd plasmid was prepared by us, as described [44, 52].
The luciferase reporter construct encoding the human TXNIP promoter
region and the plasmid encoding for human TXNIP were kindly pro-
vided by Dr. Anath Shalev (University of Wisconsin-Madison, Madison,
WI, USA). All primers were synthesized by Sigma-Aldrich. FL-926-A16
was kindly provided by Flamma S.p.A (Chignolo d’Isola, Bergamo,
Italy). Organic solvents were from Frutarom (Haifa, Israel) and Mal-
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linckrodt Baker (Deventer, Holland). All chemicals and reagents for
LC-MS/MS were of analytical-grade and purchased from Sigma-Aldrich
Chemical Co. (Milan, Italy). High-performance liquid chromatography
(HPLC)-grade water was prepared with a Milli-Q water purification
system. Optimal cutting temperature (OCT) compound for cryosection
was purchased from Bar-Naor Ltd. (Ramat Gan, Israel).
Preparation of oxidized lipoproteins
OxLDL was prepared at the Lipidomics Department, the Nicolae Simi-
onescu Institute of Cellular Biology and Pathology (Bucharest, Roma-
nia). Briefly, native LDL was isolated from plasma of healthy donors by
ultracentrifugation (Hematology Center, Bucharest, Romania). OxLDL
was prepared in vitro by incubating nLDL under sterile conditions with
10 lM copper chloride (24 hrs, at 37°C), in the absence of antioxidant
protection. The oxidative reaction was stopped by addition of 1 mg/ml
EDTA and after extensive dialysis against PBS, pH 7.4, 4°C, oxLDL was
stored at 4°C, under sterile conditions. The copper-OxLDL was charac-
terized as previously described [53].
Cell culture
Bovine aortic endothelial cell cultures
Primary cultures were isolated, cultured and characterized as described previ-
ously [54]. The cells were used up to passage 9, unless otherwise indicated.
THP-1 Monocyte
THP-1 cells, purchased from American Type Culture Collection (Rock-
ville, MD, USA), were grown in suspension in complete RPMI 1640
medium according to the supplier’s protocol. To induce differentiation
to macrophages, the THP-1 monocytes (106/ml) were exposed to
0.1 lM of PMA for 24 hrs. Foam cell formation was induced by incu-
bating the macrophages with 100 lg/ml of OxLDL for 72 hrs.
Transwell cultures
Vascular endothelial cell were plated and grown to confluency in 6-well
culture plates using complete DMEM. THP-1 cells were transformed into
macrophages or foam cells on transwell insert membranes, as
described above. The membranes were then washed three times with
fresh DMEM and inserted into the wells over the apical side of the VEC
monolayers. The co-culture was continued for the indicated periods. Cell
viability was determined by Trypan blue exclusion assay.
Senescence-associated b-galactosidase assay
The SA-b-Gal activity was determined in VEC monolayers according to
the manufacturer’s instructions (Abcam). Briefly, cells were washed,
fixed and stained with the X-Gal reagent at pH 6, followed by DAPI
staining for visualization of cell nuclei. The percentage of SA-b-Gal posi-
tive cells relative to the total DAPI-positive nuclei was assessed by
counting an area of 0.55 mm2, per images (under 910 magnifying lens)
obtained from three independent experiments using the Nikon confocal
microscope software (NIS-Elements AR 4 30.0).
Western blot analysis
Vascular endothelial cell lysates were prepared and used for Western
blot analysis. Briefly, cells were rinsed three times with PBS and lysed
with NP-40 lysis buffer (Tris HCl 50 mM pH 7.5, NP-40 1%, sodium
deoxycholate 0.25%, EGTA 1 mM, EDTA 1 mM, NaCl 150 mM, sodium
orthovanadate 1 mM, sodium fluoride 1 mM, sodium b-glycerophos-
phate 10 mM, sodium pyrophosphate 5 mM, PMSF 1 mM, protease
inhibitor cocktail 1%; Sigma). Bradford assay was used to determine
protein concentrations in the lysates. Twenty lg protein samplers were
loaded per lane and separated by PAGE and transferred to nitrocellulose
membranes. The membranes were blocked with TBST containing 5%
(wt/v) bovine serum albumin. For the analysis of TXNIP PBS contain-
ing10% (wt/v) low fat dry milk was used for blocking. Incubations with
the various antibodies were according to the suppliers’ protocols at the
following dilutions: anti-p16 (1:500), anti-p21 (1:1000), anti-phosphory-
lated pRB (1:1000), anti-TXNIP (1:500), anti-a-tubulin (1:30,000).
HPLC analysis of 4-HNE
Polar lipids were extracted from macrophage or foam cell culture media
and used to determine 4-HNE content by HPLC, as described before
[42]. Briefly, medium was collected for analysis from confluent cell cul-
tures maintained with serum-free RPMI 1640 medium for 16 hrs. This
was important in order to prevent 4-HNE-protein adduct formation. Fol-
lowing extraction of polar lipids and HPLC, the elution peak of 4-HNE
(223 nm) was detected at 4.2 min. The recovery of the standard, added
to fresh samples prior to extraction, was 85–90%. Peaks in the HPLC
profiles were monitored and quantified by using Clarity-Lite software
(DataApex Co., Prague, Czech Republic).
LC-MS/MS analysis
Analysis of FL-926-A16 adducts with 4-HNE, acrolein, glyoxal and
methyglyoxal in culture media of THP-1 macrophages or foam cells was
performed as described previously [55]. The details of the analysis are
given in the Supporting information section.
hTXNIP overexpression
Vascular endothelial cell plated in 6-well dishes were transfected at
60% confluency with the hTXNIP-lacZ expression plasmid or the
empty plasmid [56] using TransIT-LT1 reagent, according to the
manufacturer’s instructions (Mirus Bio-Corporation). Briefly, DNA
(2.5 lg) was complexed with the transfection reagent for 20 min. in
OptiMEM medium, then the mixture was added to cells in complete
growth medium for an ON incubation. Cells were harvested after
3 days for analysis of TXNIP or after 7 days for analysis of senes-
cence markers.
siRNA transfection
Vascular endothelial cell plated at 50% confluency in 6-well dishes
were transfected with 25 nM of the siRNA for bovine TXNIP or
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scrambled RNA sequences, using TransIT-TKO (Mirus Bio-Corpora-
tion). The RNA sequence was complexed with the transfection
reagent for 20 min in OptiMEM and added to cells in complete
growth medium. The medium was changed 24 hrs later, and the
cells were co-cultured with foam cells in a transwell system for addi-
tional 72 hrs, as described above. The cells were then harvested and
processed for Western blot analysis. The target sequence for bovine
TXNIP silencing was 50-CAGAAGUUGUCAUCAGUCA-30.
Luciferase assay
Vascular endothelial cell cultures, at 60% confluency, were co-trans-
fected with DNA complexed to TransIT-LT1 (Mirus Bio-Corporation)
as described above. Analysis of PPAR and TXNIP activation were
performed as previously described [44, 52]. Briefly, PPAR activation
was monitored in cells that were transfected with 165 ng of expres-
sion vectors for human (h)PPAR-a, hPPAR-c1, hPPAR-c2 or hPPAR-
d, along with of the retinoid X receptor (hRXR, 82.5 ng), green fluo-
rescent protein (82.5 ng) and Renilla luciferase (100 ng) expression
vectors, and the 3XPPRE-TK-luciferase reporter (500 ng). For analysis
of TXNIP activation, cells were co-transfected with a luciferase-repor-
ter construct encoding the human TXNIP promoter region 1777 bp
upstream of the ATG start codon (0.5 lg) with renilla luciferase
reporter plasmid (0.1 lg). Luciferase-induced luminescence was
determined by using the Mithras LB-940 luminometer (Berthold Tech-
nologies, Bad Wildbad, Germany); results were normalized to the Re-
nilla luciferase activity, used as an internal control, according to the
kit’s instructions.
Immunofluorescent staining
Human atherosclerotic plaques removed from the carotid bifurcation of
patients following endarterectomy and left internal mammary arteries
(LIMA), removed during coronary artery bypass graft, were embedded
in OCT compound and frozen sections prepared for Immunofluores-
cence. Cryosections (7 lm thick) were prepared and immunostained
with monoclonal antibodies against Factor VIII (1:500; green) and either
p21 (1:500, red) or TXNIP (1:100, red) for 16 hrs at 4°C; cell nuclei
were visualized with DAPI staining. Secondary antibodies AlexaFluor488-
and AlexaFluor647-labelled anti-rabbit and anti-mouse (1:800) were
applied for 2 hrs at room temperature. Visualization was by confocal
microscopy. The study was approved by the Hadassah Hebrew Univer-
sity Medical Center Institutional Review Board and each patient signed
an informed consent.
Statistical analysis
Data are given as mean  SEM. One sample Student’s t-test was
used to validate statistical differences in experiments expressing data
as percent of control. Statistical significance of differences between
groups was determined by multiple comparison one-way ANOVA, fol-
lowed by the Dunnett’s test using the GraphPad Prism statistical soft-
ware.
Results
Foam cells induce senescence in VEC
The capacity of foam cells to induce senescence in VEC was assessed
in an in vitro co-culture transwell assay: THP-1 monocytes, seeded
on transwell membranes, were first differentiated into macrophages
by PMA treatment and then transformed into foam cells following
exposure to OxLDL, as described in ‘Materials and methods’. Positive
Red oil O staining confirmed the formation of lipid-laden foam cells,
whereas the control macrophages (PMA-treated only) incorporated
negligible amount of the dye (Fig. S1). A significant increase in SA-b-
gal staining and the enlarged morphology typical of senescent cells
were observed in VEC co-cultured with foam cells (Fig. 1A). Western
blot analysis (Fig. 1B) showed that VEC monolayer co-cultured with
foam cells presented increased expression of p21 and p16 and
reduced level of phosphorylated (Ser795) retinoblastoma protein (p-
pRB). Together, these results show the ability of foam cells to induce
senescence in VEC via secretion of soluble factor(s).
Senescence is induced by 4-HNE in VEC
Next, we studied whether 4-HNE was released from foam cells and
could mediate senescence induction. HPLC analysis of polar lipid
extracts of media collected from PMA-treated THP-1 cells and from
foam-cell cultures showed increased secretion of 4-HNE (3.5  0.4-
fold higher than the control, Fig. 2A). The effect of exogenously added
4-HNE on senescence in VEC was assessed following exposure to 1
and 10 lM 4-HNE for 7 days. Treatment with 10 lM 4-HNE
increased the proportion of senescent cells, demonstrated by cellular
enlargement and positive staining for SA-b-gal (Fig. 2B). This effect
was accompanied by a 40  7.2% reduction in cell number per plate.
In addition, increased expression of p16 and p21 and decreased p-
pRB were most prominent at this concentration of 4-HNE (Fig. 2C).
Taken together, these findings suggest that 4-HNE mediates foam
cell-induced VEC senescence.
To further confirm this suggestion, we investigated whether the
scavenging of 4-HNE in the transwell system could blunt foam cell-
induced VEC senescence. FL-926-A16 is a potent scavenger of bioac-
tive aldehydes, including 4-HNE (European Patent EP 2519507 B1,
US Patent 8623900 B2 and [57]). Unlike the natural scavenger, L-car-
nosine, which is degraded by carnosinase in human cells [58], its
alcohol derivative FL-926-A16 is resistant to degradation. LC-MS/MS
analysis of culture medium from control (PMA-treated) macrophages
and foam cells exposed to FL-926-A16 showed that the latter cova-
lently bound 4-HNE (Fig. S2). Interestingly, this analysis also revealed
that, in addition to 4-HNE, foam cells secreted glyoxal, methyl glyoxal
and acrolein, which were also scavenged by FL-926-A16. When added
to the medium of the co-culture system, FL-926-A16 reduced the
level of p16 and p21 and increased p-pRB level (Fig. 3), supporting
the suggestion that the scavenged molecules, including 4-HNE,
induce senescence.
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TXNIP mediates 4-HNE-induced senescence
It has been suggested that increased TRX activity protects VEC
from atherogenesis [59]. TXNIP, the natural inhibitor of TRX, plays
a prominent role in regulating TRX activity in VEC; high TXNIP lev-
els were associated with endothelial cell dysfunction [49, 50, 60].
Figure 4A suggests the involvement of TXNIP in passage-induced
replicative senescence in VEC. Indeed, overexpression of TXNIP in
low passaged VEC cultures (transfected with the hTXNIP-lacZ
expression plasmid) augmented the expression of p21 and
reduced p-pRB levels (Fig. 4B). Next, we studied the effect of
exogenously added 4-HNE on TXNIP expression and its impact on
oxidative stress-induced senescence and found increased TXNIP
expression in VEC incubated with 10 lM 4-HNE for 7 days
(Fig. 4C). Importantly, TXNIP expression was increased in VEC
co-cultured with foam-cells (Fig. 4D). The 4-HNE scavenger FL-
926-A16 decreased TXNIP expression in VEC co-cultured with
foam cells (Fig. 4E), supporting the hypothesis that lipid peroxida-
tion products are involved in the up-regulation of TXNIP expres-
sion. Noteworthy, silencing of TXNIP in VEC co-cultured with foam
cells prevented the induction of the senescence markers (Fig. 4F).
Scrambled RNA sequences had no influence on TXNIP and senes-
cence marker expression (Fig. S3). Collectively, these results sug-
gest that 4-HNE up-regulates TXNIP expression and support a role
for the latter in both replicative and stress-induced senescence in
VEC.
A
B
Fig. 1 Foam cell-induced senescence in
VEC in the transwell co-culture system.
(A) Senescence-associated b Galactosi-
dase (SA-b-Gal) activity. VEC and THP-1
macrophages (M) or foam cells (FC) were
maintained in transwell co-cultures for
72 hrs, as described under ‘Materials and
methods’. The VEC monolayers were then
washed, fixed and stained with X-Gal or
DAPI as described. SA-b-Gal positive cells
and total cell number were quantified from
three different fields in each well. Results
are expressed as percent of SA-b-Gal
positive VEC (mean  SEM, n = 3;
*P < 0.05 for differences from VEC+M
control); scale bar, 100 lm. (B) Expres-
sion of senescence markers. At the end of
the co-culture period, VEC were harvested,
lysed and analysed by Western blot for
the expression of p21, p16 and phospho-
Ser795-pRB (p-pRB). Shown are repre-
sentative Western blots and quantification
of the different senescence markers.
Results are expressed as mean  SEM,
n = 3; *P < 0.05, for differences from the
respective M-treated VEC (taken as
100%).
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Fig. 2 The lipid peroxidation product
4-HNE induces senescence in VEC. (A)
THP-1 macrophages (M) and foam cells
(FC) were prepared as described under
‘Materials and methods’. The culture med-
ium was changed to serum free-medium
for 16 hrs. The medium was then col-
lected, cell debris was cleared off by cen-
trifugation and lipids were extracted and
taken for HPLC analysis of polar lipids.
The level of 4-HNE, normalized to lg of
protein, in the M extracts was taken as
arbitrary unit (1). Results are expressed
as mean  SEM, n = 3. *P < 0.05 for
differences from the respective control.
(B) Senescence-associated b-Galactosi-
dase (SA-b-Gal) activity in 4-HNE-treated
cells. VEC were treated daily with 1 or
10 lM HNE for 7 days. At the end of the
incubation period, VEC were processed
and analysed as described under the leg-
end of Figure 1A. Results are expressed
as percent of SA-b-Gal positive VEC
(mean  SEM, n = 3; *P < 0.05, for dif-
ferences from vehicle-treated controls);
scale bar, 100 lm. (C) Expression of
senescence markers. At the end of the
incubation period with 4-HNE, the cells
were harvested, lysed and processed as
described under the legend of Figure 1B.
Shown are representative Western blots
and quantification of the various markers
studied. Results are expressed as
mean  SEM, n = 3; *P < 0.05, for dif-
ferences from the respective 4-HNE
untreated controls, taken as 100%.
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The role of PPARd in foam cell-induced
senescence
Others and we have shown that 4-HNE activates PPARd [42, 43];
hence we investigated whether this mechanism is also involved in
4-HNE-induced senescence in VEC. Figure 5A shows that the selec-
tive PPARd antagonist GSK0660 abolished 4-HNE effects on the
expression of the different senescence markers and prevented the up-
regulation of TXNIP. In addition, VEC were exposed for 48 hrs to
selective agonists for the various PPAR receptors at their effective
concentrations, as described by us before in the same VEC culture
[44]. The selective PPARd agonist, GW501516, markedly augmented
TXNIP expression, whereas, the PPARa agonist Wy14643 and the
PPARc agonist, troglitazone, did not modify significantly TXNIP
expression (Fig. 5B). The hypothesis that 4-HNE activates PPARd in
VEC was further investigated by assessing the transactivation of
PPRE-coupled luciferase reporter [44]. Briefly, VEC were co-transfect-
ed with the PPAR response element (PPRE)-luciferase reporter vector
(3xPPRE-TK-Luciferase) and a combination of a specific human PPAR
vector and RXR expression vector, followed by a 48 hrs treatment
with 4-HNE (Fig. 5C). A significant increase in luciferase activity in
cells exposed to 10 lM 4-HNE was observed only in cells over-
expressing the human PPARd. The expression of PPARa was not
altered in the presence of 4-HNE, whereas the expression of PPARc1
and PPARc2 was somewhat reduced. To further test whether PPARd
mediated the enhancement of TXNIP transcription by 4-HNE, VEC
were transfected with the human TXNIP promoter (1777 bp upstream
of the ATG start codon)-luciferase vector. TXNIP promoter activity
was increased by 4-HNE and reduced in the presence of the PPARd
antagonist GSK0660 (Fig. 5D).
VEC senescence in human carotid atherosclerotic
plaques
Finally, we verified the relevance of the above findings to human ath-
erosclerosis. Figure 6 shows sections of a human carotid atheroscle-
rotic plaque stained for the endothelial cell marker Factor VIII (green),
and p21 or TXNIP (red) in the near-plaque area. The co-localization of
TXNIP or p21 with Factor VIII in the shoulder region of the plaque
suggests that endothelial cells expressing TXNIP are prone to senes-
cence. No staining of TXNIP or p21 was observed in Factor VIII-posi-
tive cells from sections of LIMA, which are resistant to cholesterol
buildup and atherosclerosis [61, 62] (Fig. 6, bottom panels).
Discussion
Cellular senescence has been linked to endothelial cell dysfunction
and atherosclerosis [14, 63]. In the present study we investigated the
mechanism involved in foam cell-induced VEC senescence. Using a
co-culture system, in which VEC were exposed on the apical side to
soluble factors released by foam cells [23, 25], we found that the lat-
ter produced soluble factors that promoted SIPS in VEC. Our findings
Fig. 3 Scavenging of 4-HNE reduces the
expression of senescence markers in VEC
co-cultured with foam cells. THP-1 mono-
cytes seeded in transwell inserts were
transformed to foam cells (FC) as
described under legend to Figure 1A, and
then co-cultured with VEC for 72 hrs, in
the absence or presence of 10 mM FL-
926-A16, with daily addition of the scav-
enger. At the end of the incubation period,
the cells were harvested, lysed and pro-
cessed for Western blotting as described
under the legend to Figure 1B. Shown are
representative Western blots and quantifi-
cation of the various senescence markers.
Results are expressed as mean  SEM,
n = 3; *P < 0.05 for differences from the
untreated cultures.
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provide an important insight into the signal transduction pathway that
culminated in endothelial cell senescence: foam cells derived from
macrophages following exposure to OxLDL secreted lipid peroxida-
tion products, including the nucleophilic aldehyde 4-HNE. The latter
interacted with VEC and activated the nuclear factor PPARd, which
transactivated the TXNIP promoter. Consequently, TXNIP expression
was increased, promoting senescence in the endothelial cells (see
model in Fig. 7).
Non-enzymatic lipid peroxidation of PUFA and their metabo-
lites, promoted by ROS, is known to generate various a,b-unsat-
urated aldehydes [29, 31]. Moreover, since these products are
often more stable than ROS, they can diffuse into other tissues
and propagate oxidative injury. Among these, 4-HNE is consid-
ered one of the most abundant and bioactive species. Its plasma
concentration in healthy individuals is estimated to be around
1 lM, whereas in disease states it may reach much higher levels
[64]. Lipid peroxidation products are known to affect the redox
balance during ageing and are involved in VEC dysfunctions,
including apoptosis, monocyte adhesion to VEC and inflammation;
the latter has been suggested recently to result from 4-HNE-
induced ER stress [37]. Our study shows that exposure of mac-
rophages to OxLDL results in the formation of lipid-laden foam
cells that produce several lipid peroxidation products including
4-HNE, which induced VEC senescence at non-cytotoxic
concentrations. The stable L-carnosine derivative FL-926-A16,
which scavenges lipid peroxidation products, attenuated foam
cell-induced VEC senescence. Collectively, these observations sug-
gest that lipid peroxidation products, such as 4-HNE, mediate the
effect of foam cells on VEC senescence. Among the known prop-
erties of 4-HNE is its biphasic activity: at low concentrations it
presents a signalling function via activation of the nuclear factor
PPARd, whereas at high concentrations it acts as a cytotoxic
agent [31, 42, 43]. Interestingly, our previous studies showed
that endothelial cells do not produce detectable amounts of 4-
HNE [44]. Therefore, it appears that exogenous 4-HNE that dif-
fuses from foam cells is involved in VEC senescence.
An important target of 4-HNE in VEC is the TRX system
which is suggested to be involved in the etiology of several
human diseases, including atherosclerosis [46]. It has been
shown before that 4-HNE interacts with and attenuates the func-
tion of the TRX system in various cells, including VEC [51, 65,
66]. The present study shows that 4-HNE may also affect the
TRX system indirectly by augmenting the expression of its natu-
ral inhibitor, TXNIP. Recent studies have shown that TXNIP pro-
moted endothelial inflammation and increased leucocyte adhesion
to endothelial cells under conditions of disturbed blood flow that
characterize blood vessel regions prone to atherosclerosis [50].
The present study shows that increased TXNIP expression in
VEC, either following treatment with 4-HNE or by overexpression
of human TXNIP, enhanced VEC senescence. Importantly, the
silencing of Txnip, which partially inhibited foam cell-induced
senescence in VEC, suggests that TXNIP is a downstream target
of 4-HNE in this process.
Others and we have previously shown that 4-HNE is an activator
of the nuclear factor PPARd [42, 43]. Using both pharmacological
and molecular tools we now show that PPARd activation is also
involved in 4-HNE-induced VEC senescence. Treatment with 4-HNE of
VEC transfected with the different human PPAR isotypes showed spe-
cific activation of PPARd, but not PPARa. Interestingly, 4-HNE
reduced the activity of PPARc1 and c2. In this context, it should be
noted that reduced PPARc activity has been linked to the induction of
senescence in photo-irradiated human fibroblasts [67]. In addition,
GSK0660, a selective PPARd antagonist [68], attenuated the effects
of 4-HNE on senescence and TXNIP expression. These findings led to
the hypothesis that TXNIP is a putative target for PPARd in VEC.
Indeed, the transactivation assay in the presence of 4-HNE and the
antagonist GSK0660 support the involvement of PPARd in this pro-
cess.
TXNIP has been linked to atherosclerosis by several in vivo
and in vitro studies [50, 69]. Here, we show by immunofluores-
cence staining of sections from atherosclerotic arteries that both
TXNIP and the p21 senescence marker were present in the endo-
thelial cells near the plaque area, supporting the relationship
between TXNIP and senescence in vivo. Endothelial cells of
LIMA, which are not prone to atherosclerosis, stained neither for
TXNIP nor for p21.
What could be the outcome of premature senescence on the
vascular endothelium? As opposed to age-related senescence,
Fig. 4 The role of TXNIP in VEC senescence. (A) TXNIP expression in VEC at different passages was analysed by Western blot. P < 0.07, for differ-
ences from cells at passage 8 (n = 3). (B) VEC were transfected with the hTXNIP-lacZ expression plasmid or with an empty vector. Cells were then
harvested and taken for Western blot analysis of TXNIP and senescence markers; results are expressed as mean  SEM, n = 3; *P < 0.05 for dif-
ferences from cells transfected with the empty vector. (C) VEC cultures were treated with the indicated concentrations of 4-HNE for 3 days, with a
daily change of medium. Cell lysates were prepared and used for Western blot analysis of TXNIP. The level of TXNIP in untreated controls was taken
as 100%. Results are expressed as mean  SEM, n = 3; *P < 0.05 for differences from the control. (D) VEC co-cultured with THP-1 macrophages
(M) or foam cells (FC) as described above, and analysed for TXNIP expression. TXNIP expression levels in the VEC + M group was taken as 100%.
Results are expressed as mean  SEM, n = 3; *P < 0.05 for differences from the control groups. (E) VEC co-cultured with foam cells (FC) in the
absence (control) or presence of 10 mM FL-926-A16, as described under the legend to Figure 3, and analysed for TXNIP expression. Results are
expressed as mean  SEM, n = 3; *P < 0.05 for differences from the control groups. (F) VEC were transfected with TXNIP siRNA and taken
24 hrs later for co-culture with foam cells (FC) for additional 72 hrs. VEC were then lysed and taken for Western blot analysis of TXNIP or of the
senescence markers. The level of TXNIP and the senescence markers in untransfected controls was taken as 100%. Representative Western blots
quantification of TXNIP and of various senescence markers are shown. Results are expressed as mean  SEM, n = 3; *P < 0.05 for differences
from respective controls (n = 3).
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involving shortening of the telomeres, which is irreversible, telo-
mere-independent SIPS is potentially a reversible process. Brod-
sky et al. [70] have shown that ebselen, a peroxynitrite
scavenger and antioxidant, prevented and reversed senescence in
early-passaged human umbilical vein endothelial cell cultures.
This also occurred in ebselen-fed Zucker diabetic fatty rats, in
which the symptoms of vasculopathy were reduced, accompanied
by prevention and reversal of endothelial cell senescence in their
aorta. Similarly, N-acetyl-cysteine reversed stress-induced senes-
cence in bone marrow-derived hematopoietic stem-cells, further
supporting the hypothesis that SIPS is reversible [17, 71]. The
association between senescence and atherosclerosis and the
potential reversibility of telomere-independent SIPS, as opposed
to telomere dependent replicative senescence, suggest that the
A B
C
D
Fig. 5 PPARd modulates the expression of TXNIP and senescence markers in VEC. (A) VEC were treated with 10 lM 4-HNE without (control) or
with 1 lM GSK0660 (GSK) for 7 days with daily changes of medium. The expression of TXNIP and the senescence markers was determined in
lysed cells by Western blot analysis. The level of TXNIP and the senescence markers in control lysates was taken as 100%. *P < 0.05 for differ-
ences from the respective controls (mean  SEM, n = 3). (B) VEC cultures were maintained for 48 hrs without (control) or with the indicated agon-
ists for PPARa, -c and -d. Cells were then taken for Western blot analysis of TXNIP expression. *P < 0.05, for differences from control cells
treated with vehicle only. (C) VEC cultures were transfected with the following expression vectors: pSG5-hPPARa, pCMX-hPPARc1, pCMX-hPPARc2
or pCDNA-hPPARd and co-transfected with pSVPORT-hRXR, pEGFP-N1 plasmid, 3xPPRE-TK-Luciferase reporter plasmid and Renilla luciferase
plasmid. The cells were incubated for 48 hrs. During the last 24 hrs of incubation the cultures were incubated without (control) or with 1 or 10 lM
4-HNE. The cells were then harvested, lysed and the relative luciferase activity was determined and normalized as described under ‘Materials and
methods’. *P < 0.05, for differences from the respective controls, taken as 1 unit (mean  SEM, n = 3). (D) VEC cultures were co-transfected with
a luciferase reporter construct containing the human TXNIP promoter and with the Renilla luciferase reporter plasmid, as described under ‘Materials
and methods’. After 24 hrs of incubation the medium was changed and cells were incubated for additional 24 hrs without (control) or with 10 lM
4-HNE in the absence or presence of 1 lM GSK0660. Cells were then lysed and taken for the luciferase activity assay as described above. The rela-
tive luciferase activity was normalized to untreated control. *P < 0.05, for differences from the indicated groups (mean  SEM, n = 3).
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former may be more relevant in the context of vascular pathol-
ogy. Therefore, better understanding of the mechanisms of
stress-induced senescence is important for devising means to
control atherosclerosis by reversing or attenuating this process in
VEC. Our study shows that in addition to the well-known effects
of oxidative stress, 4-HNE, TXNIP and PPARd mediate SIPS, and
thus may serve as potential targets for the prevention of VEC
senescence. The modulation of these targets attenuated foam
cell-induced SIPS in vitro. Specifically, we showed that attenua-
tion of SIPS could be achieved by: (i) scavenging of foam-cell
derived lipid peroxidation products, in particular the long-lived
bioactive aldehyde 4-HNE; (ii) reduction of TXNIP expression and
(iii) inhibition of PPARd activity. In conclusion, better character-
ization of the newly identified pathway(s) of 4-HNE-induced pre-
mature senescence in VEC (Fig. 7) may provide new insight into
the molecular mechanisms of this process and identify potential
targets for therapeutic intervention.
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Data S1 Foam cell-derived 4-hydroxynonenal induces endothelial cell
senescence in a TXNIP-dependent manner.
Fig. 6 Double immunofluorescence stain-
ing for Factor VIII and p21 or TXNIP in
sections of human carotid plaque or from
LIMA. Human atherosclerotic plaques
were removed from the carotid bifurcation
of patients by endarterectomy and frozen
in OCT as described in ‘Materials and
methods’. Immunostaining of tissue sec-
tions with monoclonal antibodies against
Factor VIII (green) and either p21 or
TXNIP (red) was performed. Cell nuclei
were stained with DAPI. Merged images in
the right panels demonstrate co-localiza-
tion of p21 and TXNIP with Factor VIII
(top panels). LIMA sections were used as
negative control; scale bar 20 lm. The
images are representative of three sam-
ples of human carotid plaques and two
samples of LIMA.
Fig. 7 Suggested model of foam cell-induced VEC senescence. Foam
cell-derived lipid peroxidation products, among which 4-HNE, reach VEC
and activate PPARd and subsequently increase the expression of TXNIP
which augments oxidative stress and VEC senescence.
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